Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 5/20 | 0.40 |
| ▸ | DUT | P33316 | 3/20 | 0.34 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.33 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.32 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.32 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.31 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL917968 | 0.75 | TYMP (0.40) | TYMPDUTP2RY14SLC6A1SLC6A11 | |
| SCHEMBL6363039 | 0.75 | TYMP (0.40) | TYMPDUTP2RY14P2RY2P2RY4 | |
| SCHEMBL13715991 | 0.75 | TYMP (0.48) | TYMPP2RY14P2RY2P2RY4 | |
| SCHEMBL3918343 | 0.75 | TYMP (0.48) | TYMPP2RY14P2RY2P2RY4 | |
| SCHEMBL3918341 | 0.75 | TYMP (0.48) | TYMPP2RY14P2RY2P2RY4 | |
| SCHEMBL2108638 | 0.73 | TYMP (0.46) | TYMPP2RY14P2RY2P2RY4 | |
| SCHEMBL2108637 | 0.73 | TYMP (0.46) | TYMPP2RY14P2RY2P2RY4 | |
| SCHEMBL12434636 | 0.72 | TYMP (0.62) | TYMPP2RY14P2RY2P2RY4 | |
| SCHEMBL918583 | 0.72 | TYMP (0.62) | TYMPP2RY14P2RY2P2RY4 | |
| SCHEMBL918582 | 0.72 | TYMP (0.62) | TYMPP2RY14P2RY2P2RY4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8809357-B2 | Compounds and derivatizations of DNAs and RNAs on the nucleobases of pyrimidines for function, structure and therapeutics | HUANG, ZHEN, DR. | 2014-08-19 | — | — | US | disclosed |
| US-20120070825-A1 | Novel Compounds and Derivatizations of DNAs and RNAs on the Nucleobases of Pyrimidines for Function, Structure and Therapeutics | SENA RESEARCH, INC. (US) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120070825-A1 | Novel Compounds and Derivatizations of DNAs and RNAs on the Nucleobases of Pyrimidines for Function, Structure and Therapeutics | NSUN2, RNMT, TRDMT1 | TYMP 14/4885DUT 10/4885P2RY14 1909/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.